Transluminal dilation/goniotomy with Streamline device appears effective through 6 months

Transluminal dilation and goniotomy with the Streamline surgical system appears safe and effective in the treatment of eyes with primary open angle glaucoma (POAG) of various severity types through 6 months, according to a study presented at ASCRS 2023.

In a retrospective review of eyes with a POAG diagnosis (mild/moderate: 29; severe: 14; indeterminate: 2) receiving transluminal dilation/goniotomy with Streamline, primary outcomes included changes from baseline in intraocular pressure (IOP) and the number of glaucoma medications at 1-, 3-, and 6-months. The eyes were separated based on phacoemulsification status (standalone Streamline [SL]: 19; combined Streamline and phacoemulsification [SL+IOL]: 26) and compared using Pearson’s chi-squared tests. Secondary outcomes included eyes achieving an IOP ≤ 17 mmHg and ≥ 20% IOP reduction from baseline at 6 months.

At 6 months, IOP was significantly reduced from baseline in both groups. The SL group showed a 40% reduction in IOP, from 26.1 + 5.8 mmHg to 15.7 + 4.0 mmHg (P < 0.01; n = 11), while the SL+IOL group showed a 29% reduction in IOP, from 20.9 + 2.8 mmHg to 14.9 + 2.1 mmHg (P < 0.01; n = 8). The number of glaucoma medications remained unchanged in the SL group and was reduced by one medication in all eyes receiving SL+IOL. An IOP ≤ 17 mmHg was achieved in 73% of SL versus 88% of SL+IOL (P = 0.44), and 91% of SL versus 50% of SL+IOL experienced IOP reduction by ≥ 20% (P = 0.05).

No vision-threatening complications were observed in either group, and no surgical re-interventions were performed.

Reference
Dorairaj SK, et al. 6-Month Outcomes of Transluminal Dilation and Goniotomy with Surgical System. Presented at: ASCRS Annual Meeting 2023.